CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ZymoGenetics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ZymoGenetics, Inc.
1201 Eastlake Avenue East
Phone: (206) 442-6600p:206 442-6600 Seattle, WA  98102  United States Ticker: ZGENZGEN
This company was Merged or Acquired on 10/12/2010.
This company ceased filing statements with the SEC on 10/22/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
ZymoGenetics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. During the year ended December 31, 2009, through a series workforce and cost reductions, the Company restructured its organization and are focused on developing and commercializing a limited number of products. Its portfolio includes one commercial product, RECOTHROM Thrombin, topical (Recombinant), and three immunology product candidates, which include Pegylated Interferon-lambda (PEG-IFN-lambda), Interleukin-21 (IL-21) and Interleukin-31 monoclonal antibody (IL-31 mAb). The Company’s out-licensed products include Atacicept, IL-21 monoclonal antibody (IL-21 mAb), rFactor XIII, IL-17 receptor C (IL-17RC) soluble receptor, IL-20 monoclonal antibody (IL-20 mAb) and IL-22 receptor subunit alpha monoclonal antibody (IL-22RA mAb).
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201012/31/2009YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Bruce L.Carter 66 1/1/2009 1/1/1987
Chief Executive Officer, Director Douglas E.Williams 52 1/9/2009 11/1/2004
President, Director JeremyLevin 10/8/2010 10/8/2010
12 additional Officers and Directors records available in full report.

General Information
Number of Employees: 323 (As of 12/31/2009)
Outstanding Shares: 86,584,072 (As of 8/31/2010)
Shareholders: 7,600
Stock Exchange: NASD
Federal Tax Id: 911144498
Fax Number: (206) 442-6608
Email Address: info@zgi.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023